{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-027993","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2023-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.069060+00:00","generated_at":"2026-06-10T02:11:36.406348+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Zevra Therapeutics appoints Neil F. McFarlane as CEO effective Oct 10, 2023","bullets":["Neil F. McFarlane named President and CEO, succeeding interim CEO Christal Mickle who remains Chief Development Officer.","McFarlane receives $700k base salary, 60% target bonus, 600k stock options, and 200k RSUs vesting over 4 years.","Relocation assistance of $350k provided; severance includes 1x salary (1.5x upon change in control).","Board member Joseph B. Saluri resigned effective immediately after McFarlane's appointment.","McFarlane brings 25+ years biopharma experience, most recently CEO of Adamas Pharmaceuticals."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-027993","json":"https://secwatch.observer/filing/0001437749-23-027993.json","markdown":"https://secwatch.observer/filing/0001437749-23-027993.md","text":"https://secwatch.observer/filing/0001437749-23-027993.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923027993/0001437749-23-027993-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923027993/zvra20231005_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T02:11:36.406348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"304f46558e","claim":"Joseph B. Saluri resigned as Board member at ZEVRA THERAPEUTICS, INC..","evidence_excerpt":"Resignation of Joseph B. Saluri from B","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923027993/0001437749-23-027993-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Board member"}],"fact_type":"executive_change"},{"claim_id":"8bb3b52b80","claim":"Neil F. McFarlane was appointed as President and Chief Executive Officer at ZEVRA THERAPEUTICS, INC..","evidence_excerpt":"appointed Neil F. McFarlane to serve as the Company’s President and Chief Executive Officer, effective October 10, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923027993/0001437749-23-027993-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"a21bd5f8d7","claim":"Neil F. McFarlane was appointed as member of the Board at ZEVRA THERAPEUTICS, INC..","evidence_excerpt":"Concurrently with his appointment as President and Chief Executive Officer, Mr. McFarlane was appointed to serve as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923027993/0001437749-23-027993-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"member of the Board"}],"fact_type":"executive_change"},{"claim_id":"ae92495a54","claim":"Christal M.M. Mickle changed role as Chief Development Officer at ZEVRA THERAPEUTICS, INC..","evidence_excerpt":"succeeding Christal M.M. Mickle., the Company’s former interim President and Chief Executive Officer, in such role. Ms. Mickle will continue serving in her role as Chief Development Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923027993/0001437749-23-027993-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down as interim President and Chief Executive Officer, continues as Chief Development Officer"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}